Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

福尔菲里 医学 阿柏西普 贝伐单抗 伊立替康 奥沙利铂 内科学 养生 氟尿嘧啶 结直肠癌 肿瘤科 安慰剂 胃肠病学 外科 化疗 癌症 病理 替代医学
作者
Eric Van Cutsem,Josep Tabernero,Radek Lakomý,Hans Prenen,Jana Prausová,Teresa Macarulla,Paul Ruff,Guy A. Van Hazel,Vladimir Moiseyenko,David Ferry,Joe McKendrick,Jonathan Polikoff,Alexia Tellier,R Castan,Carmen J. Allegra
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:30 (28): 3499-3506 被引量:1286
标识
DOI:10.1200/jco.2012.42.8201
摘要

Purpose Treatment for metastatic colorectal cancer (mCRC) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevacizumab or an epidermal growth factor receptor monoclonal antibody. We studied the effect of adding the novel antiangiogenic agent aflibercept (also known as ziv-aflibercept in the United States) to FOLFIRI in patients with mCRC previously treated with oxaliplatin, including patients who received prior bevacizumab. Patients and Methods Patients were randomly assigned to receive aflibercept (4 mg/kg intravenously; 612 patients) or placebo (614 patients) every 2 weeks in combination with FOLFIRI. Treatment was administered until disease progression or unacceptable toxicity. The primary end point was overall survival. Results Adding aflibercept to FOLFIRI significantly improved overall survival relative to placebo plus FOLFIRI (hazard ratio [HR], 0.817; 95.34% CI, 0.713 to 0.937; P = .0032) with median survival times of 13.50 versus 12.06 months, respectively. Aflibercept also significantly improved progression-free survival (PFS; HR, 0.758; 95% CI, 0.661 to 0.869; P < .0001), with median PFS times of 6.90 versus 4.67 months, respectively. The effects on overall survival and PFS exhibited a consistent trend across prespecified subgroup analyses, including bevacizumab pretreated patients. Response rate was 19.8% (95% CI, 16.4% to 23.2%) with aflibercept plus FOLFIRI compared with 11.1% (95% CI, 8.5% to 13.8%) with placebo plus FOLFIRI (P = .0001). Adverse effects reported with aflibercept combined with FOLFIRI included the characteristic anti–vascular endothelial growth factor effects and also reflected an increased incidence of some chemotherapy-related toxicities. Conclusion Aflibercept in combination with FOLFIRI conferred a statistically significant survival benefit over FOLFIRI combined with placebo in patients with mCRC previously treated with oxaliplatin.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
LSY发布了新的文献求助10
1秒前
小明完成签到 ,获得积分10
1秒前
1秒前
猴子魏发布了新的文献求助10
5秒前
机智冬瓜发布了新的文献求助30
5秒前
上官若男应助HMM采纳,获得10
6秒前
7秒前
7秒前
zxy发布了新的文献求助10
8秒前
来栖完成签到 ,获得积分10
9秒前
gogoal完成签到,获得积分10
9秒前
kkk完成签到,获得积分10
11秒前
14秒前
瑾宜完成签到,获得积分20
14秒前
wang完成签到,获得积分20
16秒前
悲凉的数据线完成签到 ,获得积分10
16秒前
Simin发布了新的文献求助10
18秒前
橙子完成签到,获得积分10
18秒前
19秒前
迷人八宝粥完成签到,获得积分10
19秒前
早点发SCI发布了新的文献求助10
20秒前
咩咩发布了新的文献求助10
20秒前
Cedricharr1s完成签到,获得积分10
21秒前
老实新筠发布了新的文献求助10
22秒前
所所应助minmin采纳,获得10
24秒前
25秒前
阿曼尼完成签到 ,获得积分10
26秒前
瘦瘦的涵瑶完成签到,获得积分10
26秒前
鲸海完成签到 ,获得积分10
27秒前
昌白亦发布了新的文献求助10
28秒前
28秒前
ztt完成签到,获得积分10
28秒前
zhugao应助疯狂的寄柔采纳,获得30
29秒前
华仔应助震动的沉鱼采纳,获得10
29秒前
Boyce完成签到,获得积分10
31秒前
微笑的绝悟完成签到,获得积分10
33秒前
33秒前
JamesPei应助TH采纳,获得10
34秒前
Owen应助犹豫的白梦采纳,获得10
35秒前
高分求助中
Sustainability in ’Tides Chemistry 2000
Sustainability in ’Tides Chemistry 1500
Studien zur Ideengeschichte der Gesetzgebung 1000
The ACS Guide to Scholarly Communication 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Handbook of the Mammals of the World – Volume 3: Primates 805
Ethnicities: Media, Health, and Coping 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3070968
求助须知:如何正确求助?哪些是违规求助? 2724863
关于积分的说明 7487905
捐赠科研通 2372232
什么是DOI,文献DOI怎么找? 1257934
科研通“疑难数据库(出版商)”最低求助积分说明 610139
版权声明 596906